Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Tanaz Sharifnia"'
Autor:
Tanaz Sharifnia, Mathias J. Wawer, Amy Goodale, Yenarae Lee, Mariya Kazachkova, Joshua M. Dempster, Sandrine Muller, Joan Levy, Daniel M. Freed, Josh Sommer, Jérémie Kalfon, Francisca Vazquez, William C. Hahn, David E. Root, Paul A. Clemons, Stuart L. Schreiber
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Cancer cells possess unique molecular features that can confer an increased dependence on specific genes. Here, the authors use CRISPR-Cas9 screens to identify selectively essential genes and therapeutic targets in chordoma.
Externí odkaz:
https://doaj.org/article/15d1d503cc354ceb925abcc12163767f
Autor:
Angela N Brooks, Peter S Choi, Luc de Waal, Tanaz Sharifnia, Marcin Imielinski, Gordon Saksena, Chandra Sekhar Pedamallu, Andrey Sivachenko, Mara Rosenberg, Juliann Chmielecki, Michael S Lawrence, David S DeLuca, Gad Getz, Matthew Meyerson
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e87361 (2014)
Although recurrent somatic mutations in the splicing factor U2AF1 (also known as U2AF35) have been identified in multiple cancer types, the effects of these mutations on the cancer transcriptome have yet to be fully elucidated. Here, we identified sp
Externí odkaz:
https://doaj.org/article/0ed24c85ef0e4b54b65f5d4ffd3aec84
Autor:
Amit Dutt, Alex H Ramos, Peter S Hammerman, Craig Mermel, Jeonghee Cho, Tanaz Sharifnia, Ajit Chande, Kumiko Elisa Tanaka, Nicolas Stransky, Heidi Greulich, Nathanael S Gray, Matthew Meyerson
Publikováno v:
PLoS ONE, Vol 6, Iss 6, p e20351 (2011)
Squamous cell lung carcinomas account for approximately 25% of new lung carcinoma cases and 40,000 deaths per year in the United States. Although there are multiple genomically targeted therapies for lung adenocarcinoma, none has yet been reported in
Externí odkaz:
https://doaj.org/article/673de0c9ebe0463b9b2bf9373abe9d5e
Autor:
Tanaz Sharifnia, Mathias J. Wawer, Amy Goodale, Yenarae Lee, Mariya Kazachkova, Joshua M. Dempster, Sandrine Muller, Joan Levy, Daniel M. Freed, Josh Sommer, Jérémie Kalfon, Francisca Vazquez, William C. Hahn, David E. Root, Paul A. Clemons, Stuart L. Schreiber
Identifying the spectrum of genes required for cancer cell survival can reveal essential cancer circuitry and therapeutic targets, but such a map remains incomplete for many cancer types. We apply genome-scale CRISPR-Cas9 loss-of-function screens to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::791e63be849b8a481155c9ad9335294a
https://doi.org/10.1101/2022.08.17.504193
https://doi.org/10.1101/2022.08.17.504193
Autor:
Filemon S. Dela Cruz, Hiroyuki Yoda, Calvin J. Kuo, William C. Hahn, Kelly Kersten, Olivier Gevaert, Michitaka Nakano, Bruce K. Hua, Yohannes Tsehay, Han Liang, Yun Rose Li, Taofeek K. Owonikoko, Yunqi Yan, Katherine N. Liu, Stephen E. Kurtz, Andrew J. Ewald, Gordon B. Mills, Matthew Dunworth, Yuhao Wang, Eloise M. Grasset, Joseph Estabrook, Nicola Long, Vasanthi S. Viswanathan, Bridget Robinson, Shubhroz Gill, Matthew C. Perrone, Ken Chen, Suresh S. Ramalingam, Robert T. Manguso, Asmita Bhattacharya, Andrea Califano, Wei Zhou, Yuhong Du, Elodie Henriet, Jordana Brown, Francisca Vazquez, Michael T. McManus, Manisha Warrier, Gabriel Eades, Anuja Sathe, Yilong Zou, Yoko Kosaka, Matthew A. Reyna, Theodore P. Braun, Daniela S. Gerhard, Matthew F. Krummel, Allan Balmain, Tamilla Nechiporuk, Hanlee P. Ji, Quin Morrow, Emek Demir, Pablo Tamayo, Jessica Minnier, Michael C. Bassik, Kevin Watanabe-Smith, Xiulei Mo, Qi-Wen Fan, Nicole Nasholm, Sagar Lonial, Stuart L. Schreiber, Brent R. Stockwell, Nina K. Serwas, Sourav Bandyopadhyay, Brian J. Druker, Christina Curtis, Yuan-Hung Lo, Olga Nikolova, Qiankun Niu, Veena Padmanaban, Yuchen Ge, Cristina E. Tognon, Anupriya Agarwal, Christopher J. Kemp, Kremena Karagyozova, Haian Fu, Trevor Bivona, Dan Georgess, Nidhi Sahni, Stefan Oberlin, Issac S. Chan, Michael G. Lerner, Matt Hangauer, Jennifer Saultz, Wing Hing Wong, Ilya Shmulevich, Christin Schmidt, Yasir Suhail, Andy Kaempf, Alan Ashworth, Saumya R. Bollam, Tanaz Sharifnia, Jesse S. Boehm, Kasper Karlsson, Carlos S. Moreno, Neil Tay, Michael Grzadkowski, Kevin C. Brennan, Subhashini Jagu, Elizabeth M. Swisher, Ben Deneen, Jessica A. Talamas, Amber R. Smith, Joel S. Bader, Vlado Dančík, Andrew L. Kung, William A. Weiss, Hildur Knutsdottir, Tania Q. Vu, Lee Cooper, Kanako Yuki, Wei-Ching Chen, Bridget K. Wagner, Evan F. Lind, Josh Dempster, Marie Menard, Carla Grandori, Andrey A. Ivanov, William Kim, Jeffrey W. Tyner, Jonathan S. Weissman, Thomas Jacob, Paul A. Clemons, Jitong Cai, Kaitlyn Spees, Dan S. Kaufman
Publikováno v:
Cell, vol 184, iss 5
Cell
Cell
The characterization of cancer genomes has provided insight into somatically altered genes across tumors, transformed our understanding of cancer biology, and enabled tailoring of therapeutic strategies. However, the function of most cancer alleles r
Autor:
Joshua M. Francis, Stuart L. Schreiber, Mathias Wawer, Patricia Cogswell, Francisca Vazquez, Nathanael S. Gray, James E. Bradner, Joanne Kotz, Ting Chen, Julian Blagg, Slim Sassi, Glenn S. Cowley, Matthew A. Lawlor, Tanaz Sharifnia, Paul A. Clemons, David E. Root, Paul A. Clarke, Ann E. Sizemore, William C. Hahn, Charles Y. Lin, Josh Sommer, Paul Workman, Amy Goodale, Francis J. Hornicek, Qingyuan Huang, Kwok K. Wong, Barbara A. Weir, Hadley E. Sheppard, Tinghu Zhang, Christopher J. Ott
Publikováno v:
Nature medicine
Chordoma is a primary bone cancer with no approved therapy1. The identification of therapeutic targets in this disease has been challenging due to the infrequent occurrence of clinically actionable somatic mutations in chordoma tumors2,3. Here we des
Autor:
Hadley E. Sheppard, Alessandra Dall’Agnese, Woojun D. Park, M. Shamim Shamim, Julien Dubrulle, Hannah L. Johnson, Fabio Stossi, Josh Sommer, Joan Levy, Tanaz Sharifnia, Mathias Wawer, Behnam Nabet, Paul A. Clemons, Stuart L. Schreiber, Paul Clarke, Rick Young, Charles Y. Lin, Paul Workman
Publikováno v:
Cancer Research. 82:6355-6355
Dysregulated gene programs are a hallmark of cancer, and oncogenic transcription factors (TFs) have emerged as key players that contribute to this cell state. Chordoma is a rare cancer derived from deregulation of the TF brachyury (encoded by the T g
Autor:
Nathanael S. Gray, Stuart L. Schreiber, Mathias Wawer, Hadley E. Sheppard, Hannah L. Johnson, Julien Dubrulle, Alessandra Dall’Agnese, Charles Y. Lin, Josh Sommer, Hamza Shamim, Fabio Stossi, Behnam Nabet, Paul Workman, Paul A. Clemons, Woojun D Park, Joan Levy, Patricia Cogswell, Tanaz Sharifnia, Richard A. Young
Publikováno v:
Cancer Research. 81:LB216-LB216
Chordomas are rare spinal tumors addicted to expression of the developmental transcription factor brachyury. In chordomas, brachyury is super-enhancer associated and preferentially downregulated by pharmacologic transcriptional CDK inhibition leading
Autor:
Mathias Wawer, Nathanael S. Gray, Stuart L. Schreiber, Fabio Stossi, M. Hamza Shamim, Joan Levy, Behnam Nabet, Tanaz Sharifnia, Hadley E. Sheppard, Paul A. Clemons, Julien Dubrulle, Patricia Cogswell, Hannah L. Johnson, Charles Y. Lin, Josh Sommer, Alessandra Dall’Agnese, Woojun D Park, Richard A. Young, Paul Workman
Publikováno v:
Elsevier
Cell Reports Medicine
Cell Reports Medicine
Summary Chordomas are rare spinal tumors addicted to expression of the developmental transcription factor brachyury. In chordomas, brachyury is super-enhancer associated and preferentially downregulated by pharmacologic transcriptional CDK inhibition
Autor:
Frederick H. Wilson, Antonio Calles, David E. Root, Stacey Gabriel, Levi A. Garraway, Eliezer M. Van Allen, Tanaz Sharifnia, Federica Piccioni, Pasi A. Jänne, Matthew Meyerson, Jong Wook Kim, Mohit Butaney, Pablo Tamayo, William C. Hahn, Jeffrey A. Engelman, Marzia Capelletti, Jill P. Mesirov, Steven M. Corsello, Cory M. Johannessen
Publikováno v:
Cancer Cell. 27(3):397-408
SummaryWe conducted a large-scale functional genetic study to characterize mechanisms of resistance to ALK inhibition in ALK-dependent lung cancer cells. We identify members of known resistance pathways and additional putative resistance drivers. Amo